((1S)- 1- ((((1S)- 1- benzyl- 3- cyclopropylamino- 2,3- di- oxopropyl)amino)carbonyl)- 3- methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester

Subscribe to Selected New Research on ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester

3 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: calpain inhibitor

Also Known As:

SNJ-1945

Bio-Agent Context: Research Results

Organic Chemicals: 40

Carboxylic Acids: 63

Acyclic Acids

Carbamates: 137

((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester: 3

Experts

1.	Tamada, Y: 1 article (09/2006)
2.	Oka, T: 1 article (09/2006)
3.	Walkup, R D: 1 article (09/2006)
4.	Azuma, M: 1 article (09/2006)
5.	Nakajima, E: 1 article (09/2006)
6.	Tochigi, A: 1 article (09/2006)
7.	Shearer, T R: 1 article (09/2006)

Related Diseases

1.	Retinal Degeneration 09/15/2006 - "CONCLUSION: Our results suggested that orally available calpain inhibitor SNJ-1945 might be a possible candidate drug for testing in preventing progression of glaucomatous retinal degeneration." 09/15/2006 - "and oral administration of SNJ-1945 inhibited proteolysis of alpha-spectrin and ameliorated retinal degeneration" 09/15/2006 - "Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester." 09/15/2006 - "The purpose of the present study was to determine if an orally available form of calpain inhibitor, ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), ameliorated retinal degeneration induced by acute hypertension in rats" 03/01/2007 - "Oral calpain inhibitor SNJ-1945 may be a candidate for testing as a medication against retinal degeneration in retinitis pigmentosa." Get all the results and reference details, order at left...
2.	Hypertension (High Blood Pressure) 09/15/2006 - "The purpose of the present study was to determine if an orally available form of calpain inhibitor, ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), ameliorated retinal degeneration induced by acute hypertension in rats" Get all the results and reference details, order at left...
3.	Stroke (Strokes) 11/19/2008 - "SNJ-1945 may therefore be a potential drug for stroke." Get all the results and reference details, order at left...
4.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 11/19/2008 - "We evaluated the effect of SNJ-1945 on the focal brain ischemia induced by middle cerebral artery occlusion (MCAO) in mice" Get all the results and reference details, order at left...
5.	Retinitis Pigmentosa (Pigmentary Retinopathy) 03/01/2007 - "Oral calpain inhibitor SNJ-1945 may be a candidate for testing as a medication against retinal degeneration in retinitis pigmentosa." Get all the results and reference details, order at left...
6 Diseases and 3 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	calpain inhibitors
2.	Spectrin
3.	Calpain
3 Drugs and Important Bio-Agents and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>